COMPANY PROFILE

Shanghai Yirijian Digital Intelligence Health Pharmaceutical

Explore full profile

A provider of digital and intelligent solutions for the pharmaceutical industry

ChinaFounded 2022Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2023

Total funding $10–50M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2022
Headquarters: China
Open positions: None listed
Dealroom signal: 15.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Apr 2023	$2.8M	$578M	Hillhouse Capital · Chuangxin Gongchang	↗
EARLY VC✓Equity / VC	Dec 2022	$41M	$454M	IDG Capital · JD Digits · CR Capital Management	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
VOVodorasloYour solution to better air quality	Sofia, Bulgaria	Operational	1	$61K	$132K
NBNormax BiomedNormax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness	Cork, Ireland	Operational
RMRVAC MedicinesMRNA platform company engaged in the research and development of innovative products such as vaccines for diseases	Singapore	Operational
ETENSEM TherapeuticsBiotechnology company focusing on high value and difficult-to-drug oncology targets	Medford, United States	Operational
LTLTZ TherapeuticsDevelops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need	Redwood City, United States	Operational
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

0 profiles shownExplore the complete relationship graph →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

ICIDG Capital
JDJD Digits
CMCR Capital Management
HCHillhouse Capital
CGChuangxin Gongchang

Talent

Book a demo to see the people

Founders /100 quality score

Key operators quality score

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

🇨🇳 China HQ

Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Yirijian Digital Intelligence Health Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Yirijian Digital Intelligence Health Pharmaceutical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.